Results 141 to 150 of about 5,163 (181)

Ceftaroline-associated Encephalopathy in Patients With Severe Renal Impairment. [PDF]

Clinical Infectious Diseases, 2020
Encephalopathy complicates beta-lactam therapy, particularly with impaired renal function, though no studies have reported ceftaroline-associated encephalopathy.
Sanjay R Mehta, Thomas Martin
exaly   +2 more sources

Ceftaroline for Severe Methicillin-Resistant Staphylococcus aureus Infections: A Systematic Review.

Open Forum Infectious Diseases, 2017
Ceftaroline is approved by the Food and Drug Administration for acute bacterial skin and skin-structure infections and community-acquired bacterial pneumonia, including cases with concurrent bacteremia.
David Kubiak
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Ceftaroline - a cause for neutropenia

Journal of Clinical Pharmacy and Therapeutics, 2013
The US Food and Drug Administration approved ceftaroline in 2010 for the treatment of community-acquired pneumonia and skin and soft-tissue infections. The most common adverse reactions are diarrhoea, nausea and rash. To present the first case of neutropenia directly related to ceftaroline.A 90-year-old female was given ceftaroline for treatment of a ...
R H, Rimawi, A, Frenkel, P P, Cook
exaly   +3 more sources

Ceftaroline: a comprehensive update

International Journal of Antimicrobial Agents, 2011
Ceftaroline is a novel broad-spectrum cephalosporin antibiotic currently under US Food and Drug Administration (FDA) review for a new drug application (NDA), filed by Cerexa, Inc. (a wholly owned subsidiary of Forest Laboratories), for the treatment of complicated skin and skin-structure infections (cSSSIs) and community-associated pneumonia (CAP). The
Darpan, Kaushik, Sudeep, Rathi, Ankit, Jain   +2 more
openaire   +2 more sources

Ceftaroline Fosamil

Hospital Pharmacy, 2011
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
Dennis J. Cada, Terri L. Levien, Danial E. Baker   +2 more
openaire   +1 more source

Antimicrobial Salvage Therapy for Persistent Staphylococcal Bacteremia Using Daptomycin Plus Ceftaroline

Clinical Therapeutics, 2014
PURPOSE: Guidelines recommend daptomycin combination therapy as an option for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia after vancomycin failure.
Warren E Rose, Glenn W Kaatz, Debra A Goff   +2 more
exaly   +2 more sources

[Ceftaroline breakpoints].

Enfermedades infecciosas y microbiologia clinica, 2015
Ceftaroline is a new cephalosporin for parenteral use. Notable among its microbiological properties is its ability to inhibit penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus and its good in vitro activity against several microorganisms of clinical interest.
Andrés, Canut, Luis, Martínez-Martínez   +1 more
openaire   +1 more source

Ceftaroline fosamil

Reactions Weekly, 2019
  +7 more sources

Ceftaroline Fosamil

Reactions Weekly, 2022
Michelle C. Simpson, Eric G. Schaefer
openaire   +2 more sources

Ceftaroline Fosamil

Reactions Weekly, 2021
  +4 more sources